Redeye leaves a research update following Klaria Pharma’s recently published Q3 2024 report. Overall, the key financials in the report were in line with our estimates. While we are encouraged by the market authorization for sumatriptan in selected EU countries, we are concerned about the lack of a licensing deal. Simultaneously, the company is in immediate need of short-term financing. While we continue to see multiple potential inflection points ahead that could elevate the share price, we make some adjustments to our estimates to account for the current uncertainties in the company.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se